QLETLI
ApprovedSmall molecule
QLETLI is one of 48 small molecule programs targeting Uveitis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
94 competitors in Uveitis
#DrugCompanyPhaseTrials
1Cellcept
RochePhase 3
Pred Forte
NovartisPhase 3
Roferon-a
RochePhase 3
Olumiant
Eli LillyPhase 3
Rayos
RRoxane Laboratories
Phase 3
Cosentyx
NovartisPhase 3
AIN457
NovartisPhase 3
Zinbryta
RochePhase 2
Avastin
BBio-Thera Solutions
Phase 3
Actemra
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QLETLI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBio-Thera Solutions